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Shen RL, Pontoppidan PE, Rathe M, Jiang P, Hansen CF,
Buddington RK, Heegaard PM, Müller K, Sangild PT. Milk diets
influence doxorubicin-induced intestinal toxicity in piglets. Am J
Physiol Gastrointest Liver Physiol 311: G324–G333, 2016. First
published July 21, 2016; doi:10.1152/ajpgi.00373.2015.—Chemo-
therapy-induced gastrointestinal (GI) toxicity is a common adverse
effect of cancer treatment. We used preweaned piglets as models to
test our hypothesis that the immunomodulatory and GI trophic effects
of bovine colostrum would reduce the severity of GI complications
associated with doxorubicin (DOX) treatment. Five-day-old pigs were
administered DOX (1  100 mg/m2) or an equivalent volume of
saline (SAL) and either fed formula (DOX-Form, n  9, or SAL-
Form, n 7) or bovine colostrum (DOX-Colos, n 9, or SAL-Colos,
n  7). Pigs were euthanized 5 days after initiation of chemotherapy
to assess markers of small intestinal function and inflammation. All
DOX-treated animals developed diarrhea, growth deficits, and leuko-
penia. However, the intestines of DOX-Colos pigs had lower intesti-
nal permeability, longer intestinal villi with higher activities of brush
border enzymes, and lower tissue IL-8 levels compared with DOX-
Form (all P  0.05). DOX-Form pigs, but not DOX-Colos pigs, had
significantly higher plasma C-reactive protein, compared with SAL-
Form. Plasma citrulline was not affected by DOX treatment or diet.
Thus a single dose of DOX induces intestinal toxicity in preweaned
pigs and may lead to a systemic inflammatory response. The toxicity
is affected by type of enteral nutrition with more pronounced GI
toxicity when formula is fed compared with bovine colostrum. The
results indicate that bovine colostrum may be a beneficial supplemen-
tary diet for children subjected to chemotherapy and subsequent
intestinal toxicity.
chemotherapy-induced mucositis; intestinal toxicity; enteral nutrition;
milk; bovine colostrum
NEW & NOTEWORTHY
In this study, preweaned pigs were used as models to study
intestinal complications after doxorubicin as models for pedi-
atric oncology patients receiving chemotherapy. This study
shows that the type of enteral nutrition is an important factor
that can influence the toxic responses related to doxorubicin
treatment. Compared with formula, bovine colostrum nutrition
provided beneficial effects against the intestinal injury, which
occurred early after doxorubicin administration.
GASTROINTESTINAL (GI) TOXICITY is a major dose-limiting adverse
effect of chemotherapy with implications for both morbidity
and mortality (12, 48). The associated symptoms include pain,
nausea, vomiting, and diarrhea, which affect nutritional status
and quality of life. These complications are related to adverse
clinical outcomes, prolonged hospitalization, and need for
parenteral nutrition. Due to mucosal barrier injury, there are
increased risks of fever and infections, potentially leading to
increasing mortality (12, 18, 48, 53). Emerging clinical strat-
egies for GI toxicity, including drugs, probiotics, and nutri-
tional interventions (3, 28, 65), have not been effective, and GI
dysfunction often hinders adequate enteral nutrition support,
which provides energy, macronutrients, and dietary bioactive
factors (37, 63). Enteral nutrition may, therefore, help to reduce
inflammatory conditions in the GI tract (1), and this could be
important in association with chemotherapy.
While the survival of childhood cancer has improved over
the last decades, it is still the leading cause of disease-related
mortality in children (62). The improved survival is partly
related to intensified and risk-stratified chemotherapy regi-
mens, which have led to increased toxicity, underlining the
need for better understanding and management of treatment-
related complications in these patients. At the forefront is
chemotherapy-induced intestinal dysfunction. The associated
malnutrition and toxic complications may lead to dose reduc-
tion or treatment delays, compromising treatment efficacy.
Nutrition could be particularly important for outcome in pedi-
atric cancer patients that are still in a state of growth and organ
maturation (4, 8). Studies also suggest that cancer and chemo-
therapy in infancy and early childhood can be more challeng-
ing to manage and may have worse outcomes compared with
that in older children (40, 42, 62), potentially due to immaturity
of organs such as the GI tract. Knowledge about this patient
group is limited, and comparable pediatric animal models for
chemotherapy-induced mucositis are relevant to provide new
basic knowledge. Until now, such models have focused mainly
on rodents (33), but their physiology differs markedly from
humans, and their small size and immature state at birth limit
their use as a translational model for infants and young chil-
dren, compared with a species like the pig (39, 51). The larger
size of preweaned and juvenile pigs also makes it easier to use
standard clinical and medical care procedures when inducing
and evaluating chemotherapy toxicity (35, 36, 45, 46, 57).
Bovine colostrum (Colos) contains many bioactive com-
pounds, such as immunoglobulin (Ig), transforming growth
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factor-, and insulin-like growth factor I that may stimulate gut
growth and function and provide mucosal protection via im-
munomodulatory effects and changes to the gut microbiota
(44). Thus Colos may promote GI mucosal protection via
antimicrobial and endotoxin-neutralizing effects, suppression
of gut inflammation, and by facilitating mucosal tissue repair.
In preterm pigs, enteral feeding with bovine Colos protects
against necrotizing enterocolitis, a severe condition with in-
flammatory and ulcerative lesions in the GI tract (24). Thus
bovine Colos might provide GI and systemic benefits in several
disease states involving damage to the GI mucosa (44).
Recent studies have used preweaned and weaned pigs as
models for chemotherapy-induced intestinal toxicity (36, 45),
and these may provide animal models to study liquid diet
interventions during a period of rapid growth and development,
similar to pediatric patients. Liquid milk-based diets are highly
digestible and easy to adjust in nutrient composition and intake
for chemotherapy patients requiring tube feeding. In this study,
we hypothesized that GI toxicity after treatment of preweaned
pigs with doxorubicin (DOX) would be reduced by feeding
bovine colostrum compared with a standard formula diet. DOX
is an anthracycline, which causes DNA intercalation and is
commonly used in many anticancer regimens, with multiple
organ toxicities, including myelosuppression, cardiotoxicity,
and GI toxicity (5, 7, 64).
MATERIAL AND METHODS
Animals, surgical preparation, clinical procedures, and chemo-
therapy. All animal procedures were approved by the Danish National
Committee on Animal Experimentation (no. 2010/561–1760). An
overview of the experimental approach is shown in Fig. 1. A total of
32 pigs (Large White  Danish Landrace) of both sexes were
obtained on the 3rd day of life after having suckled their mother from
birth. The pigs were brought to the research facilities where they were
housed in individual cages in a facility kept at a constant temperature
(30°C) with a 12:12-h light-dark cycle. Each cage contained behav-
ioral enrichments (toy-cloths) and allowed visual contact among
individual pigs.
Shortly after arrival, the pigs were anesthetized using zoletil mix
(intramuscular, tiletamine, 0.28 mg/kg; zolazepam, 0.28 mg/kg; xy-
lazine, 0.56 mg/kg; ketamine, 0.56 mg/kg; butorphanol, 0.11 mg/kg)
for placement of an orogastric feeding tube (6F Portex, Kent, UK) that
was inserted through the cheek and secured with sutures. A catheter
(Tygon OD 0.070 ID 0.040 Saint-Gobain Performance Plastics,
France) was surgically inserted into the external jugular vein, tunneled
under the skin, and exteriorized through the dorsal part of the neck and
used for blood sampling and administration of DOX. The pigs were
fed either bovine colostrum (Colos) or formula (Form), and within
each diet group pigs received DOX chemotherapy or saline (SAL),
with a randomized block design resulting in four groups with similar
distribution of initial body weight, sex, and litter of origin: DOX-
treated animals fed bovine Colos (DOX-Colos, n  9) or Form
(DOX-Form, n  9), and SAL groups fed bovine Colos (SAL-Colos,
n  7) or Form (SAL-Form, n  7). The pigs were fed every 3 h by
placing 15 ml/kg of their respective diet in a feeding trough. Volun-
tary food intake was allowed, but, if appetite was reduced, any
remaining feed was fed through the orogastric tube. The composition
of the Form diet was based on commercially available clinical nutri-
tion products, i.e., Pepdite (60 g/l; powdered enteral nutrition with
nonmilk-derived low-molecular-weight peptides, essential amino ac-
ids, carbohydrate, fat, vitamins, and minerals; Nutricia, Allerød,
Denmark), Lacprodan (50 g/l; whey protein; Arla Foods Ingredients,
Aarhus, Denmark), Miprodan (50 g/l; casein; Arla Foods Ingredients),
Calogen (50 g/l; long-chain triglyceride fat emulsion; Nutricia), Liqui-
gen (80 g/l; medium-chain triglyceride from fractionated coconut oil;
Nutricia), and Seravit-SHS (12 g/l; vitamins and trace elements;
Nutricia). The macronutrient composition in the Form diet was 5,291
kJ/l energy, 96 g/l protein, 40 g/l carbohydrate, with 36 g/l maltodex-
trins, and 79 g/l fat. The Colos was collected from Danish dairy cows
within 24 h of parturition, pooled, and spray-dried to a powder and
-irradiated to eliminate microorganisms (Biofiber-Damino, Gesten,
Denmark). The Colos powder was reconstituted in water (200 g/l) and
yielded macronutrient values of 3,986 kJ/l energy, 94 g/l protein, with
28 g/l IgG, 36 g/l carbohydrate, and 48 g/l fat.
Chemotherapy. Two days after the surgery and the start of the
respective feeding regimens, the pigs were administered a single
intravenous dose of DOX over 30 min, corresponding to 100 mg/m2
body surface area or an equivalent volume of SAL. This dose of DOX
is comparable to doses used in treatment of pediatric cancers, such as
acute lymphoblastic leukemia, and has been shown to induce intesti-
nal toxicity in weaned pigs (36). Body surface area was calculated as
70  kg body wt0.75/1,000 (10), providing 5–5.5 mg/kg DOX for
the 2.5- to 3.5-kg pigs.
Clinical assessment. Animals were monitored for clinical status,
including daily measurements of body weight, temperature, and diar-
rhea scoring. Diarrhea was assessed by visually categorizing waste
collection trays below the cages and animal staining, providing a daily
score of 0 (no stools or normal stools), 1 (mild diarrhea), or 2 (severe
diarrhea). Humane endpoints for euthanasia of animals before day 5
were as described elsewhere (46).
Hematology, CRP, and in vivo markers of intestinal function.
Blood samples were collected at baseline, immediately before admin-
istration of DOX, on day 3 and on day 5 (the time of euthanasia) for
hematology and analyses of C-reactive protein (CRP) and citrulline.
Hematological parameters included red blood cell (RBC), white blood
cells (WBC), neutrophils (NEU), lymphocytes (LYM), and platelet
(PLT) count (Advia 2120 Hematology System, Siemens, Erlangen,
Germany). These parameters have previously been shown to correlate
with toxicity in pigs (46). Circulating CRP is a marker of systemic
inflammatory response commonly used to indicate inflammation and
infection in both humans and pigs and was measured with an enzyme-
linked immunosorbent assay (ELISA) using a validated method for
pigs (21). Plasma citrulline is synthesized by enterocytes and is
considered a marker for intestinal mass and function, as well as a
marker of damage after chemotherapy (58). For detection of citrulline
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Fig. 1. Study design with enteral nutrition intervention using formula (Form)
or bovine colostrum (Colos). Catheters and feeding tubes were fitted surgically
2 days before chemotherapy. Doxorubicin (DOX) or saline (SAL) was admin-
istered on day 0. Blood samples were collected before the treatment, days 3
and 5, and analyzed for hematological parameters and C-reactive protein.
Digestive capacity of lactose was tested on day 4, and intestinal permeability
was assessed with the lactulose/mannitol test (lac/man test) on day 5 when
animals were killed. Results for doxorubicin-treated pigs fed formula (DOX-
Form, n  9), saline-treated pigs fed formula (SAL-Form, n  7), doxorubi-
cin-treated pigs fed bovine colostrum fed (DOX-Colos, n  9), and saline-
treated pigs fed bovine colostrum (SAL-Colos, n  7) are shown.
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(17), analytes extracted from serum samples were separated and
detected by ultra-performance liquid chromatography- triple quadru-
pole mass spectrometry (Waters, Milford, MA). Quantification of
citrulline was carried out using an analyzing software, QuanLynx
(Waters).
At baseline and again on day 4, the pigs were fed one bolus (15
ml/kg) of a 10% lactose solution via the feeding tubes to assess the
capacity for lactose digestion as a marker for intestinal function. The
bolus was given 3 h after the last feed instead of the normal diet.
Blood samples were collected 20 min after the bolus, and plasma
galactose levels were measured spectrophotometrically (Pentra 400,
Horiba ABX, Montpellier, France) using a commercial kit (55).
Before death on day 5, animals received a bolus (15 ml/kg) of 5%
lactulose and 5% mannitol solution via the feeding tube 3 h after the
previous meal to assess intestinal permeability. A urine sample was
collected by cystocentesis during necropsy 3–5 h after the lactulose/
mannitol (lac/man) bolus. Urinary concentrations of lactulose and
mannitol were determined spectrophotometrically (Pentra 400), and
intestinal permeability was assessed by the ratio of lactulose to
mannitol (lac/man ratio).
Necropsy and tissue collection. On day 5, the pigs were anesthe-
tized using the zoletil mix before intracardial collection of a blood
sample after which the pigs were euthanized by intracardial injection
of sodium pentobarbital, 200 mg/kg. After death was confirmed, the
abdomen was opened, and the small intestine (from the pyloric
sphincter to the ileo-cecal junction) was removed quickly, placed on
a cooled surface, and divided into three segments of equal length,
designated proximal (Prox), middle (Mid), and distal (Dist) intestine.
For each segment, two pieces of 0.5 cm were collected and fixed in
4% neutral buffered formalin. After fixation, samples were dehydrated
with ethanol, embedded in paraffin and cross-sectioned (5 m),
mounted on glass slides, and stained with hematoxylin and eosin.
Additional tissue samples from each intestinal region were snap-
frozen in liquid nitrogen for subsequent analyses. Finally, a 10-cm
piece of each region was collected for determining the proportional
weight of mucosa, relative to whole intestine. The remaining organs
were collected, and their weights recorded.
Intestinal tissue structure, brush border enzymes, and proinflam-
matory cytokines. Villus height and crypt depth were determined as
previously described (46). The proportion of the small intestine
represented by mucosa was determined by scraping off the mucosal
layer and drying (49). The frozen intestinal samples were processed
for analyses of brush border enzymes and cytokine levels, as de-
scribed elsewhere (46, 50). Briefly, the tissues were homogenized in
1% Triton X-100, and the activities of three dissacharidases (lactase,
maltase, sucrase) and three peptidases (aminopeptidase A, aminopep-
tidase N, dipeptidylpeptidase IV) were expressed as a hydrolytic rate
of 1 mol substrate released per minute at 37°C per gram wet whole
intestinal tissue. Intestinal inflammatory responses were based on
cytokine levels in the Dist region and measured using the DuoSet
ELISA Development kit (R&D Systems, Abingdon, UK) targeted for
porcine interleukin-1 (IL-1b), interleukin-6 (IL-6), interleukin 8
(IL-8), and tumor necrosis factor-	 (TNF-	), according to the man-
ufacturer’s instructions.
Intestinal proliferation, apoptosis, and structural proteins. Entero-
cyte proliferation was assessed by immunohistochemistry, staining for
Ki-67 on sections from the Mid intestine, as described previously
(60). Quantification was performed by image analysis using Vi-
siomorph 4.6 (Visiopharm). The total area of Ki-67-positive stained
nuclei were calculated and presented as a fraction of all nuclei.
Expression of PCNA was used as a marker of proliferation and that
of caspase-3 as a marker of apoptosis. -Actin and GAPDH proteins
were quantified by Western blot and used as indicators of basic
cytostructural and metabolic conditions, as previously described (25).
Briefly, 25-mg protein extracted from the Mid intestine segments was
resolved by electrophoresis and transferred onto polyvinylidene diflu-
oride membranes. The expression of PCNA, caspase-3, and -actin
was shown with specific antibodies (Santa Cruz, CA; and Abcam,
Cambridge, UK). The protein bands on the membranes were visual-
ized, and the band densities were detected by Image J (National
Institutes of Health, Bethesda, MD). Protein loading was controlled by
direct staining of the electrophoresis gels run parallel to the ones for
Western blot, using methods described previously (20).
Statistical analyses. Statistical analyses were performed with the
statistical software R (version 2.15.0). Weight gain was expressed as
the percent change in weight, relative to the start of DOX adminis-
tration. Continuous data were analyzed using mixed models (lmer
function) with the groups as independent variables and with adjust-
ments for sex, baseline body weight, and study round (3 rounds of pig
studies with evenly distributed groups and sexes) as explanatory
variables. For repeated-measures analyses, the individual pig identi-
fier was included in the model as a random effect. Normality was
assessed by means of standardized residuals and log-transformed to
account for variance heterogeneity, when necessary. Adjustments for
baseline values were included in the model for longitudinal data.
Group comparisons were done with the lsmeans package with multi-
plicity adjustments of P values with the single-step method. For
sample values lower than assay detection limit, these were assigned
the lowest value of the assay range. Diarrhea score was analyzed as
nonparametric data with the nparcomp package. P values 0.05 were
considered significant. Graphs were made with GraphPad Prism
(version 5.01; GraphPad Software, La Jolla, CA). Data are presented
as arithmetic means and SE of raw data, unless otherwise specified.
Fig. 2. Weight gain indicated as percent change relative to initial body weight
before treatment on day 0 (A) and diarrhea score (B) are presented as means 

SE. Results for doxorubicin-treated pigs fed formula (DOX-Form, n  9),
saline-treated pigs fed formula (SAL-Form, n  7), doxorubicin-treated pigs
fed bovine colostrum (DOX-Colos, n  9), and saline-treated pigs fed bovine
colostrum (SAL-Colos, n  7) are shown. a,b|Different superscript letters
indicate significant differences among groups within the same time point (P 
0.05).
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RESULTS
Clinical status and growth. All pigs continued to eat and
remained active and clinically stable during the 5-day study
period. No pigs required euthanasia according to humane
endpoints before the end of the protocol. All of the pigs gained
weight between day 0, when DOX (or SAL) was administered,
and day 2 (Fig. 2A). After day 3, weight gain decreased for
both groups of DOX pigs, resulting in stable body weight of
DOX-Colos pigs from days 3–5 and weight reduction for
DOX-Form pigs. The two groups of SAL pigs continued to
gain weight until day 5. Growth on day 5 was significantly
lower in DOX-Form pigs, compared with both groups of SAL
pigs (P  0.05, Fig. 2A), whereas weight for DOX-Colos pigs
was not different from that in SAL pigs. Initial weight gain
(days 0–2) tended to be greater for both groups of Form pigs,
compared with Colos pigs (Fig. 2A). Diarrhea was commonly
observed from day 3 after DOX administration with increasing
severity thereafter (Fig. 2B). Diarrhea scores were similar in
DOX-Form and DOX-Colos pigs. However, DOX-Form pigs
had higher diarrhea score than SAL groups on days 3 and 4,
whereas scores in DOX-Colos were not significantly elevated
until day 4, relative to SAL pigs (Fig. 2B). Diarrhea in SAL
pigs was restricted to one mild transient case at the start of the
study period. Vomiting was observed in one DOX-Form pig on
days 4 and 5. No effects on appetite or food intake were
observed.
Blood hematology and systemic inflammatory response. Ad-
ministration of DOX reduced WBC, compared with SAL on
days 3 and 5 (P  0.05, Fig. 3A). DOX also reduced LYM
values on both days, whereas NEU were not affected, and no
diet effect was detected for WBC, LYM, or NEU (Fig. 3, A–C).
On day 5, PLT values were lower in DOX vs. SAL pigs, as
analyzed for each of the diet regimens (P  0.05, Fig. 3D),
with no differences between DOX-Colos and DOX-Form.
RBC did not differ among groups (Fig. 3E). Longitudinal
measurements of CRP did not differ significantly among
groups on days 0 and 3. However, on day 5, levels were higher
for DOX-Form pigs, compared with DOX-Colos and SAL-
Form pigs (P  0.05, Fig. 3F).
Gut function markers in vivo. After 2 days of Form or Colos
feeding, and before the DOX (or SAL) was administered,
plasma galactose measured 20 min after a lactose bolus was
lower for Form than for Colos pigs (92 
 12 vs. 200 
 26
mol/l, P  0.01). On day 4, galactose values were similar for
both groups of Colos pigs, and both were higher than for the
two groups of Form pigs, regardless of SAL or DOX admin-
istration (pooled means
 SE: 36.2
 9.7 vs. 4.4
 3.4 mol/l,
P 0.05), indicating that diet, but not DOX treatment, affected
galactose uptake capacity. Among the groups, mean gut per-
Fig. 3. Circulating levels of white blood cells
(WBC; A), neutrophils (NEU; B), lympho-
cytes (LYM; C), platelets (PLT; D), red blood
cells (RBC; E), and C-reactive protein (CRP;
F) are presented as means 
 SE. Results for
doxorubicin-treated pigs fed formula (DOX-
Form, n  4–9), saline-treated pigs fed for-
mula (SAL-Form, n  4–7), doxorubicin-
treated pigs fed bovine colostrum (DOX-Co-
los, n  4–9), and saline-treated pigs fed
bovine colostrum (SAL-Colos, n  2–7) are
shown. a,b,c|Different superscript letters indi-
cate significant differences among groups
within the same time point (P  0.05).
Fig. 4. Intestinal permeability measured on day 5 as the urinary ratio of
lactulose to mannitol 3–5 h after an enteral bolus of lactulose (A), and mannitol
solution and proportion of mucosal mass relative to total intestinal mass (B) are
presented as means 
 SE. Results for doxorubicin-treated pigs fed formula
(DOX-Form, n  4–9), saline-treated pigs fed formula (SAL-Form, n  7),
doxorubicin-treated pigs fed bovine colostrum (DOX-Colos, n  8–9), and
saline-treated pigs fed bovine colostrum (SAL-Colos, n  7) are shown.
a,b|Different superscript letters indicate significant differences among groups
within the same time point (P  0.05).
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meability, as assessed by the lac/man ratio, was lowest for
DOX-Colos pigs (P  0.05 compared with DOX Form, Fig.
4A). Plasma citrulline did not differ significantly among
groups, regardless of diet or whether DOX was administered.
Intestinal and inflammatory responses. Macroscopic signs of
GI mucosal damage were not observed in any of the groups,
and only one pig from the DOX-Form group had signs of
edema in the colon. Only among the Form pigs did DOX
treatment reduce small intestinal weight (38%, P  0.05),
with less (nonsignificant) effects of DOX within the Colos pigs
(Table 1). The percentage of intestinal weight represented by
mucosa was significantly reduced in DOX-Form pigs, but not
in DOX-Colos pigs, both compared with their respective SAL
controls (P 0.05, Fig. 4B). Analyzed across the two diets, the
DOX treatment decreased intestinal weight and colon weight
compared with SAL (P  0.05), but, when analyzed for each
diet separately, only the DOX-induced reduction in intestinal
weight in Form-fed piglets was significant (30% reduction, P 
0.05, Table 1). For the weight of other internal organs, the spleen
was most affected by DOX with a reduction to 30–50%, com-
pared with SAL (P  0.05), with no effect of diet (Table 1).
Across SAL and DOX treatments, liver weight was significantly
lower in Colos pigs compared with Form (P  0.05, Table 1).
DOX-Colos pigs had the longest villi in the Mid and Dist
intestinal regions compared with DOX-Form and SAL-Colos
(P  0.05, Fig. 5A). The DOX treatment reduced crypt depths
Table 1. Organ weights at necropsy
Form Colos
SAL DOX SAL DOX
Stomach 7.3 
 0.9 7.7 
 0.7 7.5 
 0.6 8.3 
 0.7
Intestine 43.8 
 1.7b 30.2 
 2.3a 37.5 
 1.2a,b 33.2 
 2.1a
Colon 12.1 
 0.7a,b 11.1 
 1.6a 14.8 
 1.3b 12.0 
 0.7a,b
Liver 35.6 
 2.0 36.0 
 1.0 32.3 
 0.8 32.4 
 0.8
Lungs 19.4 
 1.8 15.7 
 1.3 19.5 
 3.0 19.8 
 1.6
Heart 7.8 
 0.4 7.4 
 0.5 7.6 
 0.1 7.2 
 0.4
Spleen 3.8 
 0.5b 1.3 
 0.2a 4.1 
 0.3b 2.0 
 0.2a
Kidneys 9.5 
 0.7 9.1 
 0.5 9.0 
 0.5 8.8 
 0.4
Values are means 
 SE. Organ weights are expressed relative to body
weight (g/kg). Groups are doxorubicin-treated pigs fed formula (DOX-Form,
n  9), saline-treated pigs fed formula (SAL-Form, n  7), doxorubicin-
treated pigs fed bovine colostrum (DOX-Colos, n  9), and saline-treated pigs
fed bovine colostrum (SAL-Colos, n  7). a,bDifferent superscript letters
indicate significant differences among the four groups (P  0.05).
Fig. 5. Villus height (A), crypt depth (B), villus-crypt ratio (VC-ratio; C), and activity of lactase (D), sucrase (E), maltase (F), dipeptidylpeptidase IV (DPP-IV;
G), aminopeptidase A (ApA; H), and aminopeptidase N (ApN; I) measured in the proximal (Prox), middle (Mid), and distal (Dist) regions of the small intestine,
respectively (means 
 SE) are shown. Results for doxorubicin-treated pigs fed formula (DOX-Form, n  9), saline-treated pigs fed formula (SAL-Form, n 
7), doxorubicin-treated pigs fed bovine colostrum (DOX-Colos, n 9), and saline-treated pigs fed bovine colostrum (SAL-Colos, n 7) are shown. a,b|Different
superscript letters indicate significant differences among the four groups within the same region (P  0.05).
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across all three regions and across diets, indicating lowered
crypt cell proliferation (P 0.05 for Colos and trend for Form,
Fig. 5B). Consequently, the villus-to-crypt ratios in the Mid
and Dist regions were increased in the DOX-Colos group,
compared with all the other groups (P  0.05, Fig. 5C).
Disaccharidase activities were highest in Prox and Mid
intestinal regions, while peptidase activities were highest in
Mid and Dist regions (Fig. 5, D–I). Only for Colos pigs were
the lactase, sucrose, and maltase activities higher for DOX vs.
SAL pigs (P  0.05, Fig. 5, D–F). No significant DOX effect
was detected for Form pigs. Similarly, it was only for Colos
pigs that dipeptidylpeptidase IV activity was higher for DOX
vs. SAL pigs (Fig. 5G). Concentrations of the proinflammatory
cytokines, IL-8 and IL-6 (Fig. 6) were lower in the Dist
intestine of pigs fed Colos (P  0.05 across treatments), but
only for IL-8 were values for DOX-Colos lower than for
DOX-Form pigs (P  0.05, Fig. 6A). Tissue levels of IL-1
and TNF-	 did not differ between diets and treatments.
Proliferation, apoptosis, and intracellular structure. Immu-
nohistochemistry staining of Ki-67-positive cells in the intes-
tine showed lower number of cells in DOX-Colos pigs com-
pared with SAL-Colos pigs (P  0.05), and numbers were
similar to those in the DOX-Form and SAL-Form pigs, which
showed no differences (Fig. 7, A and G). Yet there was a
significant negative effect of chemotherapy on Ki-67-positive
cells when analyzed across diets (P  0.001). Western blot of
PCNA revealed similar results in that values were lower in
DOX-Colos than in SAL-Colos pigs (P  0.05), while DOX-
Form tended to show lower values than SAL-Form pigs (P 
0.19, Fig. 7D), with no significant effects of diet. Cleaved
caspase-3 values were significantly lower in DOX-Form than
in the other three groups, which had similar levels (P  0.05
Fig. 7B). Uncleaved caspase-3 did not differ significantly
among groups (Fig. 7E), although DOX increased the values,
relative to SAL, as analyzed across diets (P  0.01). Overall,
DOX treatment decreased the -actin and GAPDH levels, with
limited effects of diet (Fig. 7, C and F).
DISCUSSION
Nutritional support is critical during treatment of pediatric
cancer patients to prevent malnutrition, which decreases che-
motherapy tolerance, increases toxicity and infection rates, and
compromises outcome (4). Enteral nutrition formulas are pre-
ferred over total parenteral nutrition because of assumed ben-
efits for the gut (37) and are recommended in patients with a
functional GI tract. Yet there is no consensus regarding the
type of enteral nutrition support for pediatric patients. Our
findings indicate that the type of liquid diet support influences
the response to the chemotherapeutic agent, DOX, and that a
diet rich in milk bioactive factors, such as bovine colostrum,
might be beneficial.
In humans, gut toxicity develops early after chemotherapy
(27), and the onset of diarrhea and weight loss 3–4 days after
treatment in the current study coincides with the onset of GI
toxicity in older, weanling piglets after a single dose of DOX
(36). Likewise, the intestinal structural response to DOX (e.g.,
decreased intestinal weight and amount of mucosa) is consis-
tent with data from studies in juvenile pigs (36). On the other
hand, the administration of DOX did not significantly change
lactose digestive capacity, gut permeability, and tissue proin-
flammatory cytokines, and possibly some intestinal responses
to DOX are less pronounced in preweaned vs. weaned juvenile
pigs, at least on day 5 after treatment. This may be explained
by a more immature inflammatory response during early life,
compared with adult patients, despite that a gut inflammatory
response is thought to be a central element in the complications
of chemotherapy across all patients (19, 26). Regardless, it is
important to note that the present results of DOX are docu-
mented in a state of early intestinal development, and effects
on a more mature intestine could be different. CRP is a
systemic marker of inflammatory and infectious complications
(38), and the elevated CRP levels in this study are consistent
with a systemic inflammatory response after DOX treatment.
Likewise, the markedly reduced spleen weight and changes in
hematology after a single dose of DOX were consistent with
reduced hematopoiesis.
Growing children and their GI tract are highly responsive to
the type of nutrition support (6, 55). In addition to macronu-
trients, bovine colostrum contains numerous bioactive com-
pounds that influence both gut maturation and systemic immu-
nity. This includes GI growth, digestive function, mucosal
immune function and inflammation, and the resident microbi-
ota. These may have contributed to the different responses of
the SAL pigs fed colostrum, compared with those fed formula.
Nevertheless, the colostrum diet fed to piglets not exposed to
DOX was associated with slower body weight gain, compared
with pigs fed formula, and colostrum did not in this study
increase the length and weight of the small intestine, villus
height, crypt depth, or activity of digestive enzymes in the SAL
pigs. Potentially, the most beneficial effects of colostral bio-
active factors are restricted to the immediate neonatal period,
consistent with the lacking effect of bovine colostrum on
intestinal nutrient function in healthy adults or stable short
bowel syndrome patients (13, 34, 47). Nevertheless, the ob-
served increases in lactose digestive capacity and reduced
permeability in colostrum-fed SAL pigs may suggest some
intestinal benefits, relative to formula. These differences could
also be related to potential direct negative effects of the chosen
formula diet. In preterm pigs, detrimental effects on gut struc-
ture and function have been induced by formulas very similar
to the one used in this study (43, 55), and the damaging effects
were at least partly related to replacing milk lactose with
Fig. 6. Tissue levels of proinflammatory cytokines interleukin-8 (IL-8; A) and
interleukin-6 (IL-6; B) in the distal region of the small intestine (means 
 SE)
are shown. Results for doxorubicin-treated pigs fed formula (DOX-Form, n 
9), saline-treated pigs fed formula (SAL-Form, n  7), doxorubicin-treated
pigs fed bovine colostrum (DOX-Colos, n  9), and saline-treated pigs fed
bovine colostrum (SAL-Colos, n  7) are shown. a,b|Different superscript
letters indicate significant differences among the four groups (P  0.05).
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maltodextrins (56). Such formulas only cause severe intestinal
inflammation and pathology in preterm pigs, not in normal
term pigs, although some intestinal functions may be nega-
tively affected also in term pigs (55).
Bioactive factors in milk have previously been reported to
ameliorate mucosal toxicity after administering chemothera-
peutic agents to rats and hamsters, and there is also some
evidence for beneficial effects in human chemotherapy patients
(11, 14, 15, 22, 23, 44, 59). Such effects include reducing
bacterial translocation across the gut mucosa in patients after
abdominal surgery (9) and reducing intestinal permeability
caused by nonsteroidal anti-inflammatory drugs that facilitate
bacterial translocation to the mesenteric lymph nodes, liver,
spleen, and peripheral blood (29, 30). The different intestinal
and systemic responses between DOX pigs fed colostrum or
formula suggests that bovine colostrum may be particularly
beneficial during inflammatory processes. This is consistent
with the beneficial colostrum effects observed for inflamma-
tory conditions in humans (44, 47, 52) and for the devastating
GI inflammatory disease in preterm infants, necrotizing entero-
colitis (24, 41, 54).
The greater mucosa proportion, villus height, lactose diges-
tive capacity, and reduced permeability in the DOX pigs fed
colostrum, relative to formula, highlight the benefits of bovine
colostrum on gut structure and function during DOX chemo-
therapy. This is corroborated by lowered IL-8 in ileal tissue
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and lower circulating CRP levels and is consistent with other
results from pigs (36, 46). The higher activities of the measured
brush-border enzymes and increased villus length, particularly
in the DOX-Colos pigs, may indicate that colostrum stimulated
intestinal regeneration after chemotherapy. Regardless, Ki-67
and PCNA analyses did not show signs of increased intestinal
proliferation on day 5 after DOX treatment, suggesting that
most of the colostrum-stimulated adaptive proliferation had
already occurred by this time point. In line with this, other
experimental studies have demonstrated a very early onset of
cellular toxicity after DOX treatment, and that intestinal re-
sponses are highly dynamic with cellular regeneration within a
few days of DOX administration (16, 61). Interestingly, we
found very low levels of cleaved caspase-3 in the DOX-Form
group, the group with the worst clinical outcome, while DOX-
Colos pigs had similar levels as SAL controls. This suggests
that the caspase-3 pathway is not dominating the DOX-related
cell death, at least not 5 days after DOX treatment, similar to
findings in other studies (16, 31). The reduced level of cleaved
caspase-3 in DOX-Form is even more evident when adjusted
relative to the level of uncleaved caspase-3. This indicates that
caspase-3 activation is somehow affected (66). The accumula-
tion of uncleaved caspase-3 in the DOX groups could indicate
altered expression as a response to chemotherapy. Conversely,
there was a more consistent negative effect of DOX on -actin
and GAPDH protein abundance, reflecting that chemotherapy
affected structural and metabolic processes of the intestinal
cells (2, 32), even 5 days after treatment. These two proteins
are normally considered high-abundance housekeeping pro-
teins with fundamental functions for most cells and are often
used for protein loading control when analyzing Western blots
(2, 32). Such cellular protein controls are, therefore, negatively
affected and, therefore, unreliable in studies of chemotherapy-
induced mucositis, as also indicated in other studies (2, 32).
We have demonstrated that preweaned pigs provide a good
model for studying the responses to chemotherapeutic agents
during early life and for evaluating liquid diets for enteral
nutrition support to address the associated toxicity and GI
disturbance. Although the incidence of cancer is low among
infants, the unique nature of the immature intestine and the
responses to chemotherapy need to be better understood for
more effective chemotherapy in this sensitive population. A
limitation of our study is the use of only a single dose of DOX.
Chemotherapeutic regimens typically involve multiple rounds
of treatment, which, combined with other drugs, increases the
toxicities. Questions remain regarding the more long-term
outcomes in both animals and children (35, 57) and whether
colostrum would shorten the recovery period, allowing for
more frequent chemotherapy.
The findings indicate that bovine colostrum or other bioac-
tive milk products may be beneficial to include into the enteral
nutrition support during chemotherapy. DOX had more severe
effects on GI parameters in Form-fed compared with Colos-fed
pigs, illustrating that the intestinal response to chemotherapy is
diet dependent. However, the colostrum diet was associated
with relatively low body weight gains, even in control pigs, and
it might be suboptimal and also unfeasible to supply bovine
colostrum as the sole source of enteral nutrition for pediatric
cancer patients for extended periods. Still, the present study
highlights how nutritional intervention may reduce toxic re-
sponses to DOX in piglets, and, consequently, we have initi-
ated a clinical study on bovine colostrum as a diet supplement
to children with leukemia receiving chemotherapy (Clinical-
Trials.gov Identifier: NCT01766804).
ACKNOWLEDGMENTS
We thank Elin Skytte, Kristina Møller, and Mandy Greig from Comparative
Pediatrics and Nutrition, Dept. of Clinical Veterinary and Animal Science,
University of Copenhagen, for help with animal procedures and laboratory
analyses. We also thank Lars Ove Dragsted from Dept. of Nutrition, Exercise
and Sports, University of Copenhagen, for generous help in providing analytic
resources to detect citrulline in plasma. Finally, we thank Christian Ritz from
Dept. of Nutrition, Exercise and Sports, University of Copenhagen, for statis-
tical counseling.
GRANTS
R. L. Shen received the Early Investigators Exchange Program Grant by the
International Pediatric Research Foundation.
DISCLOSURES
None of the authors have any conflicts of interest. University of Copenha-
gen has filed a patent application on use of bovine colostrum for human infants.
P. T. Sangild is listed as sole inventor, but has declined any share of potential
revenue arising from commercial exploitation of such a patent.
AUTHOR CONTRIBUTIONS
R.L.S., P.E.L.P., and P.M.H. performed experiments; R.L.S., P.E.L.P., P.J.,
C.F.H., and P.M.H. analyzed data; R.L.S., P.E.L.P., M.R., P.J., C.F.H., R.K.B.,
P.M.H., K.M., and P.T.S. interpreted results of experiments; R.L.S. prepared
figures; R.L.S. drafted manuscript; R.L.S., P.E.L.P., M.R., P.J., C.F.H.,
R.K.B., P.M.H., K.M., and P.T.S. edited and revised manuscript; R.L.S.,
P.E.L.P., M.R., P.J., C.F.H., R.K.B., P.M.H., K.M., and P.T.S. approved final
version of manuscript; P.E.L.P., R.K.B., K.M., and P.T.S. conception and
design of research.
REFERENCES
1. Aldhous MC, Meister D, Ghosh S. Modification of enteral diets in
inflammatory bowel disease. Proc Nutr Soc 60: 457–461, 2001.
2. Aldridge GM, Podrebarac DM, Greenough WT, Weiler IJ. The use of
total protein stains as loading controls: an alternative to high-abundance
single-protein controls in semi-quantitative immunoblotting. J Neurosci
Methods 172: 250–254, 2008.
3. Barasch A, Elad S, Altman A, Damato K, Epstein J. Antimicrobials,
mucosal coating agents, anesthetics, analgesics, and nutritional supple-
ments for alimentary tract mucositis. Support Care Cancer 14: 528–532,
2006.
4. Bauer J, Jürgens H, Frühwald MC. Important aspects of nutrition in
children with cancer. Adv Nutr Res 2: 67–77, 2011.
5. Benjamin RS, Wiernik PH, Bachur NR. Adriamycin chemotherapy–
efficacy, safety, and pharmacologic basis of an intermittent single high-
dosage schedule. Cancer 33: 19–27, 1974.
6. Bjornvad CR, Thymann T, Deutz NE, Burrin DG, Jensen SK, Jensen
BB, Mølbak L, Boye M, Larsson LI, Schmidt M, Michaelsen KF,
Sangild PT. Enteral feeding induces diet-dependent mucosal dysfunction,
bacterial proliferation, and necrotizing enterocolitis in preterm pigs on
parenteral nutrition. Am J Physiol Gastrointest Liver Physiol 295: G1092–
G1103, 2008.
7. Bleyer WA. Cancer chemotherapy in infants and children. Pediatr Clin
North Am 32: 557–574, 1985.
8. Bodánszky HE. Nutrition and pediatric cancer. Ann N Y Acad Sci 824:
205–209, 1997.
9. Bölke E, Jehle PM, Hausmann F, Däubler A, Wiedeck H, Steinbach
G, Storck M, Orth K. Preoperative oral application of immunoglobulin-
enriched colostrum milk and mediator response during abdominal surgery.
Shock 17: 9–12, 2002.
10. Bollen P, Hansen AK, Rasmussen HJ, Suckow MA. The Laboratory
Swine. Boca Raton, FL: CRC, 2000.
11. Boukhettala N, Ibrahim A, Claeyssens S, Faure M, Le Pessot F,
Vuichoud J, Lavoinne A, Breuillé D, Déchelotte P, Coëffier M. A diet
containing whey protein, glutamine, and TGFbeta modulates gut protein
metabolism during chemotherapy-induced mucositis in rats. Dig Dis Sci
55: 2172–2181, 2010.
G331MILK DIETS INFLUENCE INTESTINAL TOXICITY
AJP-Gastrointest Liver Physiol • doi:10.1152/ajpgi.00373.2015 • www.ajpgi.org
 by 10.220.33.2 on August 29, 2016
http://ajpgi.physiology.org/
D
ow
nloaded from
 
12. Brennan MT, von Bültzingslöwen I, Schubert MM, Keefe D. Alimen-
tary mucositis: putting the guidelines into practice. Support Care Cancer
14: 573–579, 2006.
13. Brinkworth GD, Buckley JD. Bovine colostrum supplementation does
not affect nutrient absorptive capacity in healthy young men. Nutr Res 23:
1619–1629, 2003.
14. von Bültzingslöwen I, Brennan MT, Spijkervet FKL, Logan R,
Stringer A, Raber-Durlacher JE, Keefe D. Growth factors and cyto-
kines in the prevention and treatment of oral and gastrointestinal mucosi-
tis. Support Care Cancer 14: 519–527, 2006.
15. Clarke J, Butler R, Howarth G, Read L. Exposure of oral mucosa to
bioactive milk factors reduces severity of chemotherapy-induced mucosi-
tis in the hamster. Oral Oncol 38: 478–485, 2002.
16. Dekaney CM, Gulati AS, Garrison AP, Helmrath AM, Henning SJ.
Regeneration of intestinal stem/progenitor cells following doxorubicin
treatment of mice. Am J Physiol Gastrointest Liver Physiol 297: G461–
G470, 2009.
17. Demacker PNM, Beijers AM, van Daal H, Donnelly JP, Blijlevens
NMA, van den Ouweland JMW. Plasma citrulline measurement using
UPLC tandem mass-spectrometry to determine small intestinal enterocyte
pathology. J Chromatogr B Analyt Technol Biomed Life Sci 877: 387–392,
2009.
18. Elting LS, Cooksley C, Chambers M, Cantor SB, Manzullo E, Ruben-
stein EB. The burdens of cancer therapy. Clinical and economic outcomes
of chemotherapy-induced mucositiss. Cancer 98: 1531–1539, 2003.
19. Goldberg J, Jacobsohn AD, Zahurak ML, Vogelsang GB. Gastrointes-
tinal toxicity from the preparative regimen is associated with an increased
risk of graft-versus-host disease. Biol Blood Marrow Transplant 11:
101–107, 2005.
20. Gürtler A, Kunz N, Gomolka M, Hornhardt S, Friedl AA, McDonald
K, Kohn JE, Posch A. Stain-Free technology as a normalization tool in
Western blot analysis. Anal Biochem 433: 105–111, 2013.
21. Heegaard PMH, Pedersen HG, Jensen AL, Boas U. A robust quantita-
tive solid phase immunoassay for the acute phase protein C-reactive
protein (CRP) based on cytidine 5=-diphosphocholine coupled dendrimers.
J Immunol Methods 343: 112–118, 2009.
22. Howarth GS, Francis GL, Cool JC, Xu X, Byard RW, Read LC. Milk
growth factors enriched from cheese whey ameliorate intestinal damage by
methotrexate when administered orally to rats. J Nutr 126: 2519–2530,
1996.
23. Inoue M, Okamura T, Sawada A, Kawa K. Colostrum and severe gut
GVHD. Bone Marrow Transplant 22: 402–403, 1998.
24. Jensen ML, Sangild PT, Lykke M, Schmidt M, Boye M, Jensen BB,
Thymann T. Similar efficacy of human banked milk and bovine colos-
trum to decrease incidence of necrotizing enterocolitis in preterm piglets.
Am J Physiol Regul Integr Comp Physiol 305: R4–R12, 2013.
25. Jiang P, Jensen ML, Cilieborg MS, Thymann T, Wan JMF, Sit WH,
Tipoe GL, Sangild PT. Antibiotics increase gut metabolism and antiox-
idant proteins and decrease acute phase response and necrotizing entero-
colitis in preterm neonates. PLoS One 7: e44929, 2012.
26. Jordan KKI, Christensen IJ, Heilmann C, Sengeløv H, Müller KG.
Pretransplant C-reactive protein as a prognostic marker in allogeneic stem
cell transplantation. Scand J Immunol 79: 206–213, 2014.
27. Keefe DM, Brealey J, Goland GJ, Cummins a G. Chemotherapy for
cancer causes apoptosis that precedes hypoplasia in crypts of the small
intestine in humans. Gut 47: 632–637, 2000.
28. Keefe DM, Rassias G, O’Neil L, Gibson RJ. Severe mucositis: how can
nutrition help? Curr Opin Clin Nutr Metab Care 10: 627–631, 2007.
29. Kim JW, Jeon WK, Kim EJ. Combined effects of bovine colostrum and
glutamine in diclofenac-induced bacterial translocation in rat. Clin Nutr
24: 785–793, 2005.
30. Kim JW, Jeon WK, Yun JW, Park Il D, Cho YK, Sung IK, Sohn Il C,
Kim BI, Yeom JS, Park HS, Kim EJ, Shin MS. Protective effects of
bovine colostrum on non-steroidal anti-inflammatory drug induced intes-
tinal damage in rats. Asia Pac J Clin Nutr 14: 103–107, 2005.
31. De Koning BAE, Lindenbergh-Kortleve DJ, Pieters R, Büller HA,
Renes IB, Einerhand AWC. Alterations in epithelial and mesenchymal
intestinal gene expression during doxorubicin-induced mucositis in mice.
Dig Dis Sci 52: 1814–1825, 2007.
32. Lee HG, Jo J, Hong HH, Kim KK, Park JK, Cho SJ, Park C.
State-of-the-art housekeeping proteins for quantitative western blotting:
Revisiting the first draft of the human proteome. Proteomics 16: 1863–
1867, 2016.
33. Logan RM, Stringer AM, Bowen JM, Yeoh ASJ, Gibson RJ, Sonis ST,
Keefe DMK. The role of pro-inflammatory cytokines in cancer treatment-
induced alimentary tract mucositis: pathobiology, animal models and
cytotoxic drugs. Cancer Treat Rev 33: 448–460, 2007.
34. Lund P, Sangild PT, Aunsholt L, Hartmann B, Holst JJ, Mortensen J,
Mortensen PB, Jeppesen PB. Randomised controlled trial of colostrum
to improve intestinal function in patients with short bowel syndrome. Eur
J Clin Nutr 66: 1059–1065, 2012.
35. Manzano M, Bueno P, Rueda R, Ramirez-Tortosa CL, Prieto AP,
Lopez-Pedrosa JM. Intestinal toxicity induced by 5-fluorouracil in pigs:
a new preclinical model. Chemotherapy 53: 344–355, 2007.
36. Martin J, Howard SC, Pillai A, Vogel P, Naren AP, Davis S, Ring-
wald-Smith K, Buddington K, Buddington RK. The weaned pig as a
model for doxorubicin-induced mucositis. Chemotherapy 60: 24–36,
2014.
37. Mercadante S. Parenteral versus enteral nutrition in cancer patients:
indications and practice. Support Care Cancer 6: 85–93, 1998.
38. Miedema KG, de Bont ES, Elferink RF, van Vliet MJ, Nijhuis CS,
Kamps WA, Tissing WJ. The diagnostic value of CRP, IL-8, PCT, and
sTREM-1 in the detection of bacterial infections in pediatric oncology
patients with febrile neutropenia. Support Care Cancer 19: 1593–1600,
2011.
39. Miller ER, Ullrey DE. The pig as a model for human nutrition. Annu Rev
Nutr 7: 361–382, 1987.
40. Mirow C, Pietsch T, Berkefeld S, Kwiecien R, Warmuth-Metz M,
Falkenstein F, Diehl B, von Hornstein S, Gnekow AK. Children 1
year show an inferior outcome when treated according to the traditional
LGG treatment strategy: a report from the German multicenter trial
HIT-LGG 1996 for children with low grade glioma (LGG). Pediatr Blood
Cancer 61: 457–463, 2014.
41. Møller HK, Thymann T, Fink LN, Frokiaer H, Kvistgaard AS,
Sangild PT. Bovine colostrum is superior to enriched formulas in stim-
ulating intestinal function and necrotising enterocolitis resistance in pre-
term pigs. Br J Nutr 105: 44–53, 2011.
42. Orbach D, Sarnacki S, Brisse HJ, Gauthier-Villars M, Jarreau PH,
Tsatsaris V, Baruchel A, Zerah M, Seigneur E, Peuchmaur M, Doz F.
Neonatal cancer. Lancet Oncol 14: e609–e620, 2013.
43. Penn AH, Altshuler AE, Small JW, Taylor SF, Dobkins KR, Schmid-
Schönbein GW. Digested formula but not digested fresh human milk
causes death of intestinal cells in vitro: implications for necrotizing
enterocolitis. Pediatr Res 72: 560–567, 2012.
44. Playford RJ, Macdonald CE, Johnson WS. Colostrum and milk-derived
peptide growth factors for the treatment of gastrointestinal disorders. Am
J Clin Nutr 72: 5–14, 2000.
45. Pontoppidan PEL, Shen RL, Cilieborg MS, Jiang P, Kissow H,
Petersen BL, Thymann T, Heilmann C, Müller K, Sangild PT. Bovine
colostrum modulates myeloablative chemotherapy-induced gut toxicity in
piglets. J Nutr 145: 1472–1480, 2015.
46. Pontoppidan PL, Shen RL, Petersen BL, Thymann T, Heilmann C,
Müller K, Sangild PT. Intestinal response to myeloablative chemother-
apy in piglets. Exp Biol Med (Maywood) 239: 94–104, 2014.
47. Rathe M, Müller K, Sangild PT, Husby S. Clinical applications of
bovine colostrum therapy: a systematic review. Nutr Rev 72: 237–254,
2014.
48. Rubenstein EB, Peterson DE, Schubert M, Keefe D, McGuire D,
Epstein J, Elting LS, Fox PC, Cooksley C, Sonis ST. Clinical practice
guidelines for the prevention and treatment of cancer therapy-induced oral
and gastrointestinal mucositis. Cancer 100: 2026–2046, 2004.
49. Sangild PT, Petersen YM, Schmidt M, Elnif J, Petersen TK, Budding-
ton RK, Greisen G, Michaelsen KF, Burrin DG. Preterm birth affects
the intestinal response to parenteral and enteral nutrition in newborn pigs.
J Nutr 132: 3786–3794, 2002.
50. Sangild PT, Sjöström H, Norén O, Fowden AL, Silver M. The prenatal
development and glucocorticoid control of brush-border hydrolases in the
pig small intestine. Pediatr Res 37: 207–212, 1995.
51. Sangild PT, Thymann T, Schmidt M, Stoll B, Burrin DG, Buddington
RK. Invited review: the preterm pig as a model in pediatric gastroenter-
ology. J Anim Sci 91: 4713–4729, 2013.
52. Shing CM, Peake JM, Suzuki K, Jenkins DG, Coombes JS. Bovine
colostrum modulates cytokine production in human peripheral blood
mononuclear cells stimulated with lipopolysaccharide and phytohemag-
glutinin. J Interferon Cytokine Res 29: 37–44, 2009.
53. Sonis ST. The pathobiology of mucositis. Nat Rev Cancer 4: 277–284,
2004.
G332 MILK DIETS INFLUENCE INTESTINAL TOXICITY
AJP-Gastrointest Liver Physiol • doi:10.1152/ajpgi.00373.2015 • www.ajpgi.org
 by 10.220.33.2 on August 29, 2016
http://ajpgi.physiology.org/
D
ow
nloaded from
 
54. Støy AC, Heegaard PM, Thymann T, Bjerre M, Skovgaard K, Boye
M, Stoll B, Schmidt M, Jensen BB, Sangild PT. Bovine colostrum
improves intestinal function following formula-induced gut inflammation
in preterm pigs. Clin Nutr 33: 322–329, 2014.
55. Thymann T, Burrin DG, Tappenden KA, Bjornvad CR, Jensen SK,
Sangild PT. Formula-feeding reduces lactose digestive capacity in neo-
natal pigs. Br J Nutr 95: 1075–1081, 2007.
56. Thymann T, Møller HK, Stoll B, Støy ACF, Buddington RK, Bering
SB, Jensen BB, Olutoye OO, Siggers RH, Mølbak L, Sangild PT,
Burrin DG. Carbohydrate maldigestion induces necrotizing enterocolitis
in preterm pigs. Am J Physiol Gastrointest Liver Physiol 297: G1115–
G1125, 2009.
57. Van Vleet JF, Greenwood LA, Ferrans VJ. Pathologic features of
adriamycin toxicosis in young pigs: nonskeletal lesions. Am J Vet Res 40:
1537–1552, 1979.
58. van Vliet MJ, Tissing WJ, Rings EH, Koetse HA, Stellaard F, Kamps
WA, de Bont ES. Citrulline as a marker for chemotherapy induced
mucosal barrier injury in pediatric patients. Pediatr Blood Cancer 53:
1188–1194, 2009.
59. van’t Land B, Meijer HP, Frerichs J, Koetsier M, Jager D, Smeets RL,
M’Rabet L, Hoijer M. Transforming growth factor-beta2 protects the
small intestine during methotrexate treatment in rats possibly by reducing
stem cell cycling. Br J Cancer 87: 113–118, 2002.
60. Vegge A, Thymann T, Lund P, Stoll B, Bering SB, Hartmann B,
Jelsing J, Qvist N, Burrin DG, Jeppesen PB, Holst JJ, Sangild PT.
Glucagon-like peptide-2 induces rapid digestive adaptation following
intestinal resection in preterm neonates. Am J Physiol Gastrointest Liver
Physiol 305: G277–G285, 2013.
61. Wang S, Konorev EA, Kotamraju S, Joseph J, Kalivendi S, Kaly-
anaraman B. Doxorubicin induces apoptosis in normal and tumor cells
via distinctly different mechanisms. Intermediacy of H2O2- and p53-
dependent pathways. J Biol Chem 279: 25535–25543, 2004.
62. Ward E, Desantis C, Robbins A, Kohler B, Jemal A. Childhood and
adolescent cancer statistics, 2014. CA Cancer J Clin 64: 83–103,
2014.
63. Xue H, Sawyer MB, Wischmeyer PE, Baracos VE. Nutrition modula-
tion of gastrointestinal toxicity related to cancer chemotherapy: from
preclinical findings to clinical strategy. JPEN J Parenter Enteral Nutr 35:
74–90, 2011.
64. Young RC, Ozols RF, Myers CE. The anthracycline antineoplastic
drugs. N Engl J Med 305: 139–153, 1981.
65. Yuan A, Sonis S. Emerging therapies for the prevention and treatment of
oral mucositis. Expert Opin Emerg Drugs 19: 343–351, 2014.
66. Zhivotovsky B. More than one road to kill tumor cells: why are they not
always successful? Cell Cycle 2: 31–33, 2003.
G333MILK DIETS INFLUENCE INTESTINAL TOXICITY
AJP-Gastrointest Liver Physiol • doi:10.1152/ajpgi.00373.2015 • www.ajpgi.org
 by 10.220.33.2 on August 29, 2016
http://ajpgi.physiology.org/
D
ow
nloaded from
 
